Abbott Laboratories 2021 Form 10-K Summary
Business context and reporting period
Abbott Laboratories filed its Form 10-K for the fiscal year ended December 31, 2021. Abbott is a diversified global health care company operating through four reportable segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. International sales represented approximately 61% of consolidated net sales, and Abbott employed approximately 113,000 people at year-end.
Financial performance and key metrics
| Metric | 2021 | 2020 | Change |
|---|---|---|---|
| Net sales | $43.075 billion | $34.608 billion | 24.5% increase |
| Operating earnings | $8.425 billion | $5.357 billion | 57.3% increase |
| Operating margin | 19.6% | 15.5% | Up 4.1 percentage points |
| Earnings from continuing operations | $7.071 billion | $4.471 billion | 58.2% increase |
| Net earnings | $7.071 billion | $4.495 billion | 57.3% increase |
| Diluted EPS | $3.94 | $2.50 | 57.6% increase |
| Net cash from operating activities | $10.533 billion | $7.901 billion | 33.3% increase |
| Capital expenditures | $1.885 billion | $2.177 billion | 13.4% decrease |
| Cash and cash equivalents | $9.799 billion | $6.838 billion | 43.3% increase |
| Total debt | $18.050 billion | $18.747 billion | Decrease |
| Working capital | $11.1 billion | $8.5 billion | Increase |
Gross profit margin was 52.2% in 2021 versus 50.5% in 2020. The effective tax rate increased to 13.9% from 10.0%, partly reflecting the absence of certain 2020 tax benefits. Abbott generated approximately $8.5 billion of operating cash flow in excess of capital expenditures and paid $3.202 billion of dividends. The company declared dividends of $1.82 per share in 2021, compared with $1.53 per share in 2020.
Segment performance
| Segment | 2021 sales | 2021 operating earnings | Key change |
|---|---|---|---|
| Established Pharmaceutical Products | $4.718 billion | $889 million | Sales up 9.6%; earnings up from $794 million |
| Nutritional Products | $8.294 billion | $1.763 billion | Sales up 8.5%; margin pressured by manufacturing and distribution costs |
| Diagnostic Products | $15.644 billion | $6.256 billion | Sales up 44.8%; earnings up 68.0% |
| Medical Devices | $14.367 billion | $4.514 billion | Sales up 21.9%; earnings up 48.6% |
COVID-19 testing-related sales increased to approximately $7.7 billion from $3.9 billion in 2020, including approximately $6.6 billion from BinaxNOW, Panbio, and ID NOW rapid testing platforms. Excluding COVID-19 testing sales, total sales increased 15.2%; excluding both COVID-19 testing and foreign exchange, sales increased 13.7%. FreeStyle Libre sales reached $3.7 billion, up 36.8% excluding foreign exchange.
Material changes versus the prior comparable period
- Revenue growth was led by strong demand for rapid COVID-19 diagnostics, recovery in medical procedure volumes, continued FreeStyle Libre growth, and broad-based international growth.
- Operating margin expanded primarily due to higher sales volumes, improved manufacturing utilization, and the nonrecurrence of the 2020 intangible-asset impairment.
- Inflation, transportation costs, supply-chain constraints, restructuring costs, foreign exchange, and pricing pressure in drug-eluting stents partially offset operating gains.
- Abbott recorded $499 million of second-quarter charges to realign its COVID-19 diagnostic manufacturing network. Subsequent demand from Delta and Omicron variants led to approximately $181 million of sales of inventory previously assigned no net realizable value and reduced remaining exit-cost estimates.
- Abbott repurchased approximately $2.016 billion of common shares in 2021 and authorized an additional $5 billion share-repurchase program in December 2021.
- Goodwill declined to $23.2 billion from $23.7 billion, while net intangible assets declined to $12.7 billion from $14.8 billion. No goodwill impairment was recorded.
Guidance, outlook, commentary, risks and unusual items
Management did not provide a specific full-year 2022 revenue or earnings forecast in the filing. For 2022, Abbott expects to continue meeting demand for COVID-19 tests, expand adoption of the Alinity diagnostics systems, broaden its Medical Devices presence, grow nutritionals globally, and expand its emerging-market pharmaceutical portfolio. Research and development spending is targeted at approximately 7% of 2022 sales.
- COVID-19 testing demand remains highly volatile and depends on variant emergence, case rates, public-health policies, vaccination levels, and regulatory authorizations. Emergency-use authorizations may expire or be revoked.
- Global supply-chain disruptions, inflation, material availability, electronic-component shortages, and transportation costs may pressure margins or limit production.
- Abbott had approximately $18.1 billion of consolidated debt, with $754 million of principal due in 2022 and $2.3 billion due in 2023. It had up to $5 billion of available unsecured revolving credit capacity and no short-term borrowings at year-end.
- Abbott expects approximately $415 million of pension contributions in 2022 and expects operating cash flow to exceed capital expenditures and cash dividends.
- Key risks include extensive product and facility regulation, reimbursement and price controls, product liability and recalls, intellectual-property disputes, cybersecurity and data-privacy incidents, foreign-exchange movements, international operations, and dependence on successful product development.
- As of January 31, 2022, Abbott was involved in 68 lawsuits concerning specialty infant formula administered to preterm infants. Abbott also was involved in patent litigation with DexCom concerning continuous glucose-monitoring products. Management believed the ultimate resolution of disclosed proceedings would not materially affect financial position, cash flows, or results of operations.
- Legal and environmental exposures were estimated at $30 million to $45 million, with approximately $40 million accrued at December 31, 2021. Unrecognized tax benefits were approximately $1.9 billion, and the remaining U.S. transition-tax obligation was approximately $794 million.
Most important facts for investors to verify
- Whether COVID-19 diagnostic sales normalize, decline, or remain elevated, and the resulting effect on revenue, inventory, capacity, and margins.
- Whether medical-device procedure volumes and FreeStyle Libre growth remain strong amid reimbursement and competitive pressures.
- Progress in offsetting inflation, supply-chain costs, restructuring charges, and foreign-exchange headwinds.
- Debt maturities, refinancing needs, credit ratings, dividend increases, and the pace of share repurchases.
- Developments in the infant-formula litigation, DexCom patent disputes, regulatory approvals, and product-safety matters.
- Accuracy of estimates for rebates, taxes, pensions, intangible-asset valuations, litigation reserves, and contingent consideration.